PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report

Hormone-resistant prostate cancer (HRPC) occurs when prostate cancer is no longer responsive to hormone therapy. Treatment options are limited, and there is a clear necessity for therapies that improve outcome. Preclinical and clinical evidence supports the role of the immunomodulatory agent lenalid...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasent Blesa, Joan Manel, Godoy, Miguel Peris, Esparcia, María Fonfría, Mollá, Sara Blasco, Magán, Balbino Mancheño, Sempere Ortells, José Miguel, Sánchez, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2012
Materias:
Published online: April, 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364036/
https://www.ncbi.nlm.nih.gov/pubmed/22666210
http://dx.doi.org/10.1159/000336481
_version_ 1782234479148924928
author Gasent Blesa, Joan Manel
Godoy, Miguel Peris
Esparcia, María Fonfría
Mollá, Sara Blasco
Magán, Balbino Mancheño
Sempere Ortells, José Miguel
Sánchez, José Luis
author_facet Gasent Blesa, Joan Manel
Godoy, Miguel Peris
Esparcia, María Fonfría
Mollá, Sara Blasco
Magán, Balbino Mancheño
Sempere Ortells, José Miguel
Sánchez, José Luis
author_sort Gasent Blesa, Joan Manel
collection PubMed
description Hormone-resistant prostate cancer (HRPC) occurs when prostate cancer is no longer responsive to hormone therapy. Treatment options are limited, and there is a clear necessity for therapies that improve outcome. Preclinical and clinical evidence supports the role of the immunomodulatory agent lenalidomide in HRPC. In this paper, we report that lenalidomide showed antitumoral activity in a patient with HRPC and bone metastases pre-treated with chemotherapy, decreased the PSA level and improved the patient's health status for the first 5 months. It is important to emphasize that it was not associated with hematologic toxicity.
format Online
Article
Text
id pubmed-3364036
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-33640362012-06-04 PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report Gasent Blesa, Joan Manel Godoy, Miguel Peris Esparcia, María Fonfría Mollá, Sara Blasco Magán, Balbino Mancheño Sempere Ortells, José Miguel Sánchez, José Luis Case Rep Oncol Published online: April, 2012 Hormone-resistant prostate cancer (HRPC) occurs when prostate cancer is no longer responsive to hormone therapy. Treatment options are limited, and there is a clear necessity for therapies that improve outcome. Preclinical and clinical evidence supports the role of the immunomodulatory agent lenalidomide in HRPC. In this paper, we report that lenalidomide showed antitumoral activity in a patient with HRPC and bone metastases pre-treated with chemotherapy, decreased the PSA level and improved the patient's health status for the first 5 months. It is important to emphasize that it was not associated with hematologic toxicity. S. Karger AG 2012-04-18 /pmc/articles/PMC3364036/ /pubmed/22666210 http://dx.doi.org/10.1159/000336481 Text en Copyright © 2012 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: April, 2012
Gasent Blesa, Joan Manel
Godoy, Miguel Peris
Esparcia, María Fonfría
Mollá, Sara Blasco
Magán, Balbino Mancheño
Sempere Ortells, José Miguel
Sánchez, José Luis
PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report
title PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report
title_full PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report
title_fullStr PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report
title_full_unstemmed PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report
title_short PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report
title_sort psa response to lenalidomide therapy in a pre-treated patient with metastatic prostate cancer refractory to hormones and chemotherapy: a case report
topic Published online: April, 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364036/
https://www.ncbi.nlm.nih.gov/pubmed/22666210
http://dx.doi.org/10.1159/000336481
work_keys_str_mv AT gasentblesajoanmanel psaresponsetolenalidomidetherapyinapretreatedpatientwithmetastaticprostatecancerrefractorytohormonesandchemotherapyacasereport
AT godoymiguelperis psaresponsetolenalidomidetherapyinapretreatedpatientwithmetastaticprostatecancerrefractorytohormonesandchemotherapyacasereport
AT esparciamariafonfria psaresponsetolenalidomidetherapyinapretreatedpatientwithmetastaticprostatecancerrefractorytohormonesandchemotherapyacasereport
AT mollasarablasco psaresponsetolenalidomidetherapyinapretreatedpatientwithmetastaticprostatecancerrefractorytohormonesandchemotherapyacasereport
AT maganbalbinomancheno psaresponsetolenalidomidetherapyinapretreatedpatientwithmetastaticprostatecancerrefractorytohormonesandchemotherapyacasereport
AT sempereortellsjosemiguel psaresponsetolenalidomidetherapyinapretreatedpatientwithmetastaticprostatecancerrefractorytohormonesandchemotherapyacasereport
AT sanchezjoseluis psaresponsetolenalidomidetherapyinapretreatedpatientwithmetastaticprostatecancerrefractorytohormonesandchemotherapyacasereport

Ejemplares similares